However, a possibility, discussed in details in another review from this issue is to use combinations of antibodies (8), where even if the antibodies mentioned earlier for the treatment of AML used separately could be also toxic for the normal tissues, their combination (CD44, CD123, CD47, and TIM-3) could use smaller doses of each one of them, avoiding the concentrations required to induce toxicity in normal cells, but still be effective killing the CSC on AML. The gene discussed is CD44; the disease is acute myeloid leukemia.